Christopher J. Spadaro
Christopher Spadaro is an associate in the Litigation Department.
Subscribe to all posts by Christopher J. Spadaro
The regulation of drug prices has received significant recent bipartisan support in Congress. Democrats and Republicans in both houses have proposed approximately eighty bills relating to drug pricing over the past two years. The charts below summarize the key provisions of representative bills.[i] Although the proposed price-regulating mechanisms differ from bill to bill, the bills … Continue Reading
Among its various attempts to regulate drug prices, the Trump administration recently sought to force pharmaceutical advertisements to disclose the wholesale acquisition cost (WAC) of certain drugs. This effort was dealt a setback in June, when the D.C. Circuit found that the Department of Health and Human Services (HHS) overstepped its regulatory authority by compelling … Continue Reading
Pre-Election Drug Pricing Regulation Efforts: Where Does Congress Stand?
By Sarah Cork and Christopher J. Spadaro on Posted in Federal Rules, Health Care, Life Sciences
HHS Can’t Force Disclosure of Drug Prices in Ads with “Blunderbuss” Rule
By Christopher J. Spadaro and Sarah Cork on Posted in Appellate, Health Care, Life Sciences
